Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VetoquinolLTS:0O1O -1.09%80 Gross Margin % is 94.25% as of Dec. 2025, which is 35% above its 10-year median of 70.02. GuruFocus rates LTS:0O1O with a GF Score™ of 80/100 and a GF Value™ of €85.90 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 943 Drug Manufacturers companies, Vetoquinol ranks better than 87.7% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Vetoquinol's Gross Profit for the
six
months ended in Dec. 2025 was €252.6 Mil. Vetoquinol's Revenue for the
six
months ended in Dec. 2025 was €268.1 Mil. Therefore, Vetoquinol's Gross Margin % for the quarter that ended in Dec. 2025 was 94.25%.
The historical rank and industry rank for Vetoquinol's Gross Margin % or its related term are showing as below:
LTS:0O1O'
s Gross Margin % Range Over the Past 10 Years
Min: 66.44 Med: 70.02 Max: 74.73
Current: 74.73
During the past 13 years, the highestGross Margin % of Vetoquinol was 74.73%. The lowest was 66.44%. And the median was 70.02%.
LTS:0O1O's Gross Margin % is ranked better than 87.7% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs LTS:0O1O: 74.73
Vetoquinol had a gross margin of 94.25% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Vetoquinol was 1.10% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vetoquinol had a gross margin of 94.25% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vetoquinol Gross Margin % Related Terms
Vetoquinol Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vetoquinol's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0O1O vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vetoquinol's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vetoquinol Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vetoquinol's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vetoquinol's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vetoquinol (LTS:0O1O) has a Gross Margin % of 94.25% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Vetoquinol and its competitors. This is 35% above median its historical median of 70.02. Over the past decade, Vetoquinol's Gross Margin % has ranged from 66.44 to 74.73. According to the industry distribution chart, Vetoquinol ranks #116 out of 943 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Vetoquinol's Gross Margin % too high?
Vetoquinol's current Gross Margin % of 94.25% is 35% above median its 10-year median of 70.02. Over the past 10 years, this metric has ranged from a low of 66.44 to a high of 74.73. The Drug Manufacturers industry median Gross Margin % is 48.54. Vetoquinol's value of 94.25% is 94.2% above this industry median. Based on the distribution chart, Vetoquinol ranks #116 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vetoquinol has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vetoquinol's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vetoquinol ranks #116 out of 943 companies for Gross Margin %. This places Vetoquinol in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Vetoquinol's value of 94.25% is 94.2% above this benchmark. Historically, Vetoquinol's own Gross Margin % has ranged from 66.44 to 74.73 over the past decade. While the company's 10-year median is 70.02 vs. the industry median of 48.54, Vetoquinol has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vetoquinol's current Gross Margin % of 94.25% is 94.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vetoquinol and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vetoquinol's current Gross Margin % is 94.25%, which is 35% above median its own 10-year median of 70.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vetoquinol stock overvalued right now?
Based on GuruFocus' analysis, Vetoquinol (LTS:0O1O) is currently considered Modestly Undervalued. The stock's GF Value™ is €85.90, compared to a current price of €72.30 — trading 15.8% below its estimated fair value. The current Gross Margin % is 94.25%, which is 35% above median its 10-year median of 70.02 and 94.2% above the Drug Manufacturers industry median of 48.54. Vetoquinol's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vetoquinol (LTS:0O1O), the current Gross Margin % is 94.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vetoquinol (LTS:0O1O) Overvalued in 2026?
Based on GuruFocus' analysis, Vetoquinol stock appears to be undervalued.
The current stock price of €72.30 is trading 15.8% below its estimated GF Value™ of €85.90.
GuruFocus considers Vetoquinol to be Modestly Undervalued.
Key valuation signals for LTS:0O1O:
Gross Margin %: 94.25% (35% above median its 10-year median of 70.02)
GF Value™: €85.90 vs. price of €72.30 (15.8% below fair value)
Industry Position: 94.2% above the Drug Manufacturers median (#116 of 943)
No single metric tells the full story. See the LTS:0O1O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
80GF Score
Get the complete analysis for LTS:0O1O
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0O1O has been successfully added to your 
